Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":816645790,"tweetId":"816645790","gmtCreate":1630500773210,"gmtModify":1631893508758,"author":{"id":3577155247763320,"idStr":"3577155247763320","authorId":3577155247763320,"authorIdStr":"3577155247763320","name":"ZhaoYingying","avatar":"https://static.tigerbbs.com/b86f603c032bb4185ad17dff4bc5cb95","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/816645790","repostId":1128019873,"repostType":4,"repost":{"id":"1128019873","kind":"news","pubTimestamp":1630499831,"share":"https://www.laohu8.com/m/news/1128019873?lang=zh_CN&edition=full","pubTime":"2021-09-01 20:37","market":"us","language":"en","title":"Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review<blockquote>Teva-MedinCell的精神分裂症治疗候选药物正在接受FDA审查</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128019873","media":"Benzinga","summary":"The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeki","content":"<p><div> The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia. TV-46000/mdc-IRM is a risperidone extended-...</p><p><blockquote><div>FDA已接受梯瓦制药工业有限公司和MedinCell寻求批准TV-46000/mdc-IRM治疗精神分裂症的上市申请。TV-46000/mdc-IRM是利培酮扩展-...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review<blockquote>Teva-MedinCell的精神分裂症治疗候选药物正在接受FDA审查</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review<blockquote>Teva-MedinCell的精神分裂症治疗候选药物正在接受FDA审查</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-09-01 20:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia. TV-46000/mdc-IRM is a risperidone extended-...</p><p><blockquote><div>FDA已接受梯瓦制药工业有限公司和MedinCell寻求批准TV-46000/mdc-IRM治疗精神分裂症的上市申请。TV-46000/mdc-IRM是利培酮扩展-...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TEVA":"梯瓦制药"},"source_url":"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128019873","content_text":"The FDA has accepted Teva Pharmaceutical Industries Ltd  and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.\nThe acceptance is based on Phase 3 data from two pivotal studies. Results will be shared at future scientific conferences and in peer-reviewed publications.\nTeva will continue to lead the clinical development and regulatory process and be responsible for the commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales, and future commercial milestones.\nTeva is also conducting another Phase 3 study designed to evaluate the long-term safety, tolerability, and effectiveness of TV-46000 subcutaneously administered for up to 56 weeks in 331 schizophrenia patients.\nThe primary endpoint is the frequency of all adverse events, including serious adverse events. This study is ongoing; interim results align with the findings of the RISE study.\nPrice Action: TEVA shares are up 0.64% at $9.48 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"TEVA":0.9}},"isVote":1,"tweetType":1,"viewCount":462,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/816645790"}